Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 10/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.74 |
| ▸ | CSF1R | P07333 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 5/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1276904 | 0.85 | KCNH2 (1.00) | SCN5AKCNH2CSF1R | |
| SCHEMBL27777073 | 0.84 | CSF1R (0.70) | SCN5AKCNH2CSF1REGFR | |
| SCHEMBL27777074 | 0.78 | SCN5A (0.60) | SCN5AKCNH2CSF1R | |
| SCHEMBL27777167 | 0.75 | CSF1R (0.63) | CSF1REGFR | |
| SCHEMBL2301922 | 0.74 | KCNH2 (0.80) | SCN5AKCNH2CSF1R | |
| SCHEMBL1579245 | 0.74 | KCNH2 (0.80) | SCN5AKCNH2CSF1R | |
| SCHEMBL2904232 | 0.73 | CSF1R (0.79) | SCN5AKCNH2CSF1R | |
| SCHEMBL1580009 | 0.72 | SCN5A (0.77) | SCN5AKCNH2CSF1R | |
| SCHEMBL1579889 | 0.72 | SCN5A (0.83) | SCN5AKCNH2CSF1R | |
| SCHEMBL1276787 | 0.71 | SCN5A (0.86) | SCN5AKCNH2CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130280251-A1 | Stabilized Angiopoietin-2 Antibodies And Uses Thereof | MEDIMMUNE LIMITED (GB) | 2013-10-24 | — | — | US | claimed |
| US-20110098283-A1 | 3-CINNOLINECARBOXAMIDE DERIVATIVES AND THEIR USE FOR TREATING CANCER | ASTRAZENECA AB | 2011-04-28 | — | — | US | claimed |
| JP-2011510632-A | — | — | 2011-04-07 | — | — | JP | claimed |
| EP-2247305-A1 | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF | MedImmune Limited (GB) | 2010-11-10 | — | — | EP | claimed |
| US-7723337-B2 | 3-cinnolinecarboxamide derivatives and their use for treating cancer | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | claimed |
| EP-2118072-A1 | 3 - CINNOLINECARBOXAMIDE DERIVATIVES AND THEIR USE FOR TREATING CANCER | AstraZeneca AB (SE) | 2009-11-18 | — | — | EP | claimed |
| WO-2009097325-A1 | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF | MEDIMMUNE LIMITED (GB) | 2009-08-06 | — | — | WO | claimed |
| US-20090012084-A1 | 3-CINNOLINECARBOXAMIDE DERIVATIVES AND THEIR USE FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | claimed |
| WO-2008090353-A1 | 3 - CINNOLINECARBOXAMIDE DERIVATIVES AND THEIR USE FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2008-07-31 | — | — | WO | claimed |
| US-10329345-B2 | Stabilized angiopoietin-2 antibodies and uses thereof | MEDIMMUNE LIMITED (GB) | 2019-06-25 | — | — | US | disclosed |
| US-20170174756-A1 | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF | ASTRAZENECA AB (SE) | 2017-06-22 | — | — | US | disclosed |
| US-20130280251-A1 | Stabilized Angiopoietin-2 Antibodies And Uses Thereof | MEDIMMUNE LIMITED (GB) | 2013-10-24 | — | — | US | disclosed |
| US-8507656-B2 | Stabilized angiopoietin-2 antibodies and uses thereof | MEDIMMUNE LIMITED (GB) | 2013-08-13 | — | — | US | disclosed |
| US-20110044998-A1 | Stabilized Angiopoietin-2 Antibodies And Uses Thereof | MEDIMMUNE LIMITED | 2011-02-24 | — | — | US | disclosed |
| EP-2247305-A1 | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF | MedImmune Limited (GB) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009097325-A1 | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF | MEDIMMUNE LIMITED (GB) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174756-A1 | STABILIZED ANGIOPOIETIN-2 ANTIBODIES AND USES THEREOF | TEK, VEGFA, THPO | SCN5A 4393/4885KCNH2 4314/4885CSF1R 118/4885 |
| US-20130280251-A1 | Stabilized Angiopoietin-2 Antibodies And Uses Thereof | TEK, VEGFA, THPO | SCN5A 4393/4885KCNH2 4314/4885CSF1R 118/4885 |
| US-10329345-B2 | Stabilized angiopoietin-2 antibodies and uses thereof | TEK, VEGFA, THPO | SCN5A 4393/4885KCNH2 4314/4885CSF1R 118/4885 |
| US-20110098283-A1 | 3-CINNOLINECARBOXAMIDE DERIVATIVES AND THEIR USE FOR TREATING CANCER | CSF3R, CSF1R, KIT | SCN5A 1667/4885KCNH2 2089/4885CSF1R 2/4885 |
| US-20090012084-A1 | 3-CINNOLINECARBOXAMIDE DERIVATIVES AND THEIR USE FOR TREATING CANCER | CSF3R, CSF1R, KIT | SCN5A 1667/4885KCNH2 2089/4885CSF1R 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.